UNSPSC 51291905: Napactadine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C14H16N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9FB1F1BV0M, chemically known as 2-naphthaleneethanimidamide, n,n-dimethyl-, monohydrochloride but more generally known as napactadine hydrochloride, which bears US NIH Compound Identifier 42152. Most nations, for tariff and trade purposes, schedule napactadine hydrochloride under HS 29252900 and SITC 51482.

As of Q4 2014, NAPACTADINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Napactadine hydrochloride bears US NLM identifiers UMLS ID C2827273 and NCI Concept Code C83984. SMILES: CN/C(=N\C)/CC1CCC2CCCCC2C1.CL.

UNSPSC 51291905 Napactadine hydrochloride is a Commodity code that covers pharmaceutical products, though recent state and local solicitations tagged with this code show limited activity directly aligned with napactadine procurement. The three most recent opportunities under this code involve broader pharmaceutical and drug-management categories: one seeks naloxone and drug deactivation systems, another is an exploratory RFI on direct-to-manufacturer prescription programs, and the third is a cooperative purchasing agreement for generic multi-source pharmaceuticals and OTC products. State and local buyers using this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances serving multiple states and municipalities (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The work solicited spans acquisition of emergency pharmaceutical interventions, establishment of direct-contracting pharmacy benefit relationships, and supply agreements for generic and over-the-counter medications distributed across state and local health facilities.

Recent activity clusters in Florida and Texas, with broader multistate reach through the Minnesota cooperative purchasing vehicle. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through July 26, 2023 (note: this date appears to be a data entry error in the source and predates the posting date). The Texas HHS Commission posted RFI HHS0017013 in April 2026 to explore vendor capabilities for direct-to-manufacturer prescription programs, with responses due April 3, 2026. MMCAP issued RFP S1070000015802 in January 2026, due March 26, 2026, to establish multi-award contracts for generic pharmaceuticals and OTC products across participating jurisdictions including Oregon, with awarded vendors effective July 1, 2026. The code shows fragmented activity across health departments and cooperative purchasing vehicles with no dominant repeat buyer evident in the recent record.